Drug Trial Radar · NCT00127530
Study of Oral Fampridine-SR in Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Sep 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
May 2005
Primary completion
Jun 2006
Study completion Sep 2006
Sponsor
- Lead sponsor
- Acorda TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 8, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the safety and efficacy of 10 milligram (mg) twice a day (b.i.d.) Fampridine-SR in patients diagnosed with multiple sclerosis (MS), in a double-blind, placebo-controlled, parallel group study.
Conditions
- Multiple Sclerosis
Interventions
Fampridine-SRDrug
Tablets, 10 mg, twice daily, 14 weeks
PlaceboDrug
sugar pill, twice a day (b.i.d.)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Timed Walk Responders (Patients Who Showed Consistent Improvement on the Timed-25 Foot Walk)Time frame: Days 14, 42, 70 and 98 of treatment, corresponding to the four on-drug visits during double-blind treatment period.
Locations
34 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
Barrow Neurology Clinic, St. Joseph's Hospital and Medical Center
Phoenix, Arizona
USC, Keck School of Medicine
Los Angeles, California
UC Davis
Sacramento, California
University of Colorado Health Sciences Center
Denver, Colorado
Multiple Sclerosis Treatment Center
Derby, Connecticut
Shepard Center
Atlanta, Georgia
University of Chicago
Chicago, Illinois
Indiana University MS Center
Indianapolis, Indiana
Maryland Center for MS
Baltimore, Maryland
Wayne State University, Department of Neurology
Detroit, Michigan
The Schapiro Center for MS
Golden Valley, Minnesota
Washington University SOM
St Louis, Missouri
Gimbel MS Center at Holy Name Hospital
Teaneck, New Jersey
University of Mexico, MIND Imaging Center
Albuquerque, New Mexico
Maimonides Medical Center
Brooklyn, New York
Corinne Goldsmith Dickinson Center for MS
New York, New York
University of Rochester
Rochester, New York
SUNY - Stony Brook
Stony Brook, New York
Carolinas Healthcare System
Charlotte, North Carolina
Cleveland Clinical Foundation
Cleveland, Ohio
Ohio State University MS Center
Columbus, Ohio
Oregon Health & Science University, MS Center of Oregon, UHS-42
Portland, Oregon
Thomas Jefferson University Physicians
Philadelphia, Pennsylvania
Allegheny General Hospital, Allegheny Neurological Associates
Pittsburgh, Pennsylvania
University of Texas - Houston
Houston, Texas
Neurological Research Center, Inc.
Bennington, Vermont
Fletcher Allen Health Care
Burlington, Vermont
MS Hub Medical Group
Seattle, Washington
University of Washington, MS Research Center
Seattle, Washington
Foothills Medical Center
Calgary, Alberta, Canada
University of British Columbia, Vancouver Coastal Health Research Institute
Vancouver, British Columbia, Canada
QEII Health Sciences Centre, Nova Scotia Rehabilitation Centre Site
Halifax, Nova Scotia, Canada
Ottawa Hospital General Campus
Ottawa, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.